RVLP earnings

-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth -- -- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company's portfolio and leverage the field force investment -- -- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year pe

BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date     Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereW

-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity -- -- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end -- -- UPNEEQ Won "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants -- BRIDGEWATER, N.J., M

BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: DateThursday, May 11, 2023Time 8:30 a.m. ETToll free (U.S.)800-579-2543International 7

-- RVLP records exceptional year-over-year growth with UPNEEQ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 -- -- Full year 2022 UPNEEQ net product sales of $34.2 million, an increase of $26.7 million, or 356%, over 2021 -- -- Preliminary fourth quarter 2022 UPNEEQ net product sales were $12.1 million; refinement to revenue methodologies results in final fourth quarter 2022 UPNEEQ net product sales of $9.8 million, an increase of $6.7 million, or 216%, over 2021; $2.3 million now recognized in first quarter 2023 -- BRIDGEWATER, N.J., March 20, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceutical

BRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its fourth quarter and full year 2022 financial results and provide a commercial update on Monday, March 20, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: DateMonday, March 20, 2023Time8:30 a.m. ETToll free (U.S.)800-343-4136In

BRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its third quarter 2022 financial results and provide a commercial update on Thursday, November 10, 2022, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows: Date                    Time                    Toll free (U.S.)In

-- Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- -- Expanded Board of Directors with the appointment of Alisa Lask, Aesthetic industry veteran with pharmaceutical experience in both sales and marketing -- -- Continued sequential expansion among key UPNEEQ demographics, including pharmacy-paid prescribers and medical aesthetics practices -- BRIDGEWATER, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced financial results and business highlights

BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2022 financial results and provide a commercial update on Thursday, August 11, 2022, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows: Date Thursday, August 11, 2022Time 8:30 a.m. ETRegister* (audio only) Click HereW

First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 Reaffirms fourth quarter 2022 UPNEEQ net product sales guidance of $20 to 25 million UPNEEQ selected as the winner of a "Best in Innovation" award in the 12th Annual Beauty Awards conducted by NewBeauty, a Sandow Publication and "Best Professional Treatment Product" in the Shape Healthy Beauty Awards BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical co

BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercial update on Thursday, May 12, 2022, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows: Date Thursday, May 12, 2022Time 8:30 a.m. ETToll free (U.S.) 866-342-8591International 203-518-9713Conference ID RVLPQ122Webcast (live and replay) www.rvlpharma.com under the "

Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million, respectively Full national launch of UPNEEQ into medical aesthetics market in February 2022 First quarter 2022 UPNEEQ product sales expected to be in the range of $5.5 to 6.0 million Fourth quarter 2022 UPNEEQ revenue guidance of $20.0 to 25.0 million reaffirmed Received $5 million from contingent milestones related to divestiture of the legacy business with additional $15.5 million expected from amendment of UPNEEQ License Agreement BRIDGEWATER, N.J., March 30, 2022 (GLOBE NEWSWIRE) -- RVL Phar

BRIDGEWATER, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 fourth quarter and full year financial results and provide an update of its first quarter 2022 Medical Aesthetic launch on Wednesday, March 30, 2022, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: DateWednesday, March 30, 2022Time 4:30 p.m. ETToll free (U.S.)(866) 672-5029International(409) 217-8312Conference ID42